Darifenacin Hydrobromide

氢溴酸达非那新

Report date: 2024/02/21 12:07:04
NME

Base Information

Drug NameDarifenacin Hydrobromide
Drug Alias Namedarifenacina氢溴酸达菲那新达非那新Darifenacinumdarifenacin +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMuscarinic acetylcholine receptor M3 antagonists
TargetsMuscarinic acetylcholine receptor M3
Therapy Area/IndicationsUrinary Incontinence, UrgeUrinary Bladder, OveractiveUrologic Diseases +[5] 
Global Approved IndicationsUrinary Incontinence, UrgeUrinary Bladder, Overactive
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2004/10/22
Country/TerritoryUnited StatesGermanyChile +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesPharmaand GmbHAbbvie IncBeijing Furuikangzheng Medicine Technology Research Institute
Inactive CompaniesUniversity Of ValparaísoNovartis Pharma AgWarner Chilcott Ltd +[4] 
Active IndicationsUrinary Incontinence, UrgeUrinary Bladder, OveractiveCarcinoma, Non-Small-Cell Lung
Inactive IndicationsUrologic DiseasesMultiple Sclerosis

Other Information

ATC CodeG04BD10
Related LinksWikipediaDrugBankKEGG